Fig. 7. Specificity and longevity of antitumor response elicited by the combination of Tranilast/m with nano-immunotherapy.
a Kaplan–Meier survival curves for the various treatments considered (n = 7–8 mice). Arrows indicate the survival fraction (SF) of mice at day 90. Statistical analysis was performed by a log-rank (Mentel-Cox) test comparing the treated groups with the control. C57BL/6 female mice were orthotopically injected with 5 × 104 E0771 cells on day 0 and subsequently treated as indicated. Primary tumors were surgically removed on day 21 and mice were daily monitored for their survival rate. On day 90, survivors of the Tranilast/m-Doxil (n = 3) and Tranialst/m-ICB-Doxil (n = 7) group were rechallenged with 5 × 104 E0771 cells in the opposite site of the first injection. A group of naïve mice of the same age was challenged in parallel to serve as a control. On day 130, tumor free mice and a group of naïve mice were challenged in parallel with the irrelevant MCA205 fibrosarcoma cell line (2.5 × 105 cells) by subcutaneous injection in the right flank. b–d Individual growth curves of naïve mice (b), cured mice of Tranilast/m-Doxil group (c) and Tranilast/m-ICB-Doxil group (d) challenged with E0771 (left) and MCA205 (right) tumor cells. The number of tumor free mice is also demonstrated in each study.